ACHV (Achieve Life Sciences) Net Cash per Share : $0.77 (As of Sep. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Achieve Life Sciences's Net Cash per Share for the quarter that ended in Sep. 2024 was $0.77.

The historical rank and industry rank for Achieve Life Sciences's Net Cash per Share or its related term are showing as below:

ACHV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.65 Med: 2.17 Max: 18.54
Current: 5.32

During the past 13 years, the highest Price-to-Net-Cash Ratio of Achieve Life Sciences was 18.54. The lowest was 0.65. And the median was 2.17.

ACHV's Price-to-Net-Cash is ranked worse than
57.76% of 838 companies
in the Biotechnology industry
Industry Median: 4.215 vs ACHV: 5.32

Achieve Life Sciences Net Cash per Share Historical Data

The historical data trend for Achieve Life Sciences's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Net Cash per Share Chart

Achieve Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

9.25

5.37

2.49

0.17

-0.25

Achieve Life Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Cash per Share	Get a 7-Day Free Trial															-0.02	-0.25	1.34	1.13	0.77

Competitive Comparison of Achieve Life Sciences's Net Cash per Share

For the Biotechnology subindustry, Achieve Life Sciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Price-to-Net-Cash falls into.

Achieve Life Sciences Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Achieve Life Sciences's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(15.496	-	20.819	-	0)	/	21.1658
=	-0.25

Achieve Life Sciences's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

	Net Cash per Share (Q: Sep. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(42.911	-	16.539	-	0)	/	34.3899
=	0.77

Achieve Life Sciences (NAS:ACHV) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Achieve Life Sciences Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Executives

Richard Alistair Stewart	director, officer: President & CEO	19820 NORTH CREEK PARKWAY, SUITE 201, BOTHELL WA 98011
John Bencich	officer: CFO and PFO	2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King	director	91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc	10 percent owner	C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn	10 percent owner	C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc	10 percent owner	2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb	10 percent owner	2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p.	10 percent owner	C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p.	10 percent owner	2770 SAND HILL ROAD, MENLO PARK CA 94025